Biomanufacturing is a $400 billion industry encompassing pharmaceuticals, biodegradable materials, alternative proteins, and industrial enzymes. However, a persistent challenge has hindered large-scale production: declining efficiency and poor yields. The root of the problem lies in cell mutations, which cause variations in productivity. As microorganisms prioritize survival over production, low-performing cells outcompete high-yielding ones, reducing overall output this will be addressing the core challenge in biomanufacturing scale-up.
Enduro Genetics is at the forefront of solving this critical challenge. The Danish biotech startup has developed a groundbreaking technology that ensures only the most efficient cells thrive, optimizing biomanufacturing for scalability and sustainability.
Eliminating Low-Performing Cells with Enduro’s Synthetic Addiction Technology
Founded in 2019 by Dr. Peter Rugbjerg and Dr. Christian Munck as a spin-out from the Technical University of Denmark, Enduro is pioneering a revolutionary approach to industrial bioprocesses. Dr. Rugbjerg’s patented synthetic addiction technology embeds a genetic plug-in into microbial production hosts, linking their survival directly to productivity. This innovative approach eliminates inefficient cells, stabilizing biomanufacturing at an industrial scale.
Dr. Rugbjerg’s research, published in Nature and PNAS, has been widely recognized in the scientific community for its impact on biomanufacturing efficiency. The company’s flagship solution, Enduro Sense, enhances performance across all microbial expression systems, regardless of the organism or product type. This ensures efficiency in existing production lines while driving innovation in new product development.
Advancing a Greener, Safer, and More Resilient Future
With industries increasingly shifting towards biomanufacturing to decarbonize operations and create eco-friendly alternatives to fossil-based products, Enduro’s technology is more relevant than ever. The company’s solution is instrumental in optimizing the production of biofuels, bioplastics, specialty chemicals, pharmaceuticals, and alternative proteins.
Enduro already collaborates with industry leaders in biopharmaceuticals, food, agriculture, and industrial sectors, demonstrating the broad applicability and effectiveness of its technology.
Industry Leaders Endorse Enduro’s Game-Changing Approach
Christian Munck, CEO of Enduro Genetics, expressed enthusiasm about the company’s latest funding round:
“This new investment marks a significant milestone for Enduro. It reflects the confidence in our technology, our team, and the market validation we have achieved. With this funding, we can accelerate commercialization, enhance our platform, and expand into biopharmaceutical expression systems. We are thrilled to take this next step with strong support from our existing and new investors.”
Dr. Peter Rugbjerg, Founder and CSO of Enduro Genetics, emphasized the long-standing challenge they are addressing:
“For decades, the biomanufacturing sector has struggled with inefficiencies due to low-performing cells. Many companies operate with processes where only a small fraction of cells contribute to high production. At Enduro, we are changing the game with optimization technology that maximizes biotechnology’s full potential. This funding will fast-track our commercialization efforts and help manufacturers scale sustainably, driving real impact across industries.”
Investors Recognize Enduro’s Disruptive Potential
Enduro’s latest funding round has garnered support from prominent investors who see the startup’s potential to reshape biomanufacturing.
Romain Sautrau, Investment Director at Supernova Invest, highlighted the game-changing nature of Enduro’s technology:
“Enduro’s innovation can be a critical enabler in breaking the cost barrier of biomanufacturing solutions, particularly in the food and chemical industries. The team’s rapid traction, bringing onboard leading biomanufacturing companies in a short span, is impressive. We look forward to working closely with Christian and Peter to support their growth.”
Theis Malmborg, General Partner at NOON Ventures, expressed confidence in Enduro’s future:
“We are doubling down on our investment in Enduro during this Series A round. The company’s cell reprogramming technology is addressing major challenges in the bioproduction space, and large organizations are already reaping its benefits. Enduro has the potential to make a massive impact on the future of biomanufacturing, and we are excited to be part of their journey.”
Funding Details
Enduro Genetics has secured €12 million in Series A funding to advance its mission of making biomanufacturing more efficient and cost-effective. The investment came from Supernova Invest (which has previously backed Loft Orbital and Alice & Bob), NOON Ventures, and Sandwater (which has supported 1X Technologies and XO Life). This latest round brings Enduro’s total funding to €18 million, including grants from the BioInnovation Institute and the European Innovation Council Accelerator Grant.
The newly raised capital will be used to expand Enduro’s platform, accelerate commercialization efforts, and further integrate its technology into biopharmaceutical expression systems.
With this breakthrough funding, Enduro Genetics is poised to redefine industrial biomanufacturing, driving sustainable, high-efficiency production solutions that benefit industries worldwide.
